| 10.5 0.24 (2.34%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.02 | 1-year : | 15.21 |
| Resists | First : | 11.14 | Second : | 13.02 |
| Pivot price | 10.31  |
|||
| Supports | First : | 8.27 | Second : | 6.5 |
| MAs | MA(5) : | 10.58 |
MA(20) : | 10 |
| MA(100) : | 7.67 |
MA(250) : | 6.91 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 66.8 |
D(3) : | 74 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 11.14 | Low : | 4.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SGMT ] has closed below upper band by 38.9%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.73 - 10.79 | 10.79 - 10.86 |
| Low: | 10 - 10.08 | 10.08 - 10.15 |
| Close: | 10.38 - 10.5 | 10.5 - 10.6 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Thu, 27 Aug 2026
Enterprise value to EBIT forward of Sagimet Biosciences Inc. - Series A – NASDAQ:SGMT - TradingView
Mon, 17 Aug 2026
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Mon, 17 Aug 2026
Three New Hires Get Stock Options That Vest Over Four Years at Sagimet - Stock Titan
Fri, 14 Aug 2026
Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan
Thu, 13 Aug 2026
Sagimet Biosciences Announces FDA Clearance of IND for Phase 3 Denifanstat Acne Trial - Quiver Quantitative
Wed, 05 Aug 2026
Sagimet Stock: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026 (NASDAQ:SGMT) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 83 (%) |
| Shares Short | 11,600 (K) |
| Shares Short P.Month | 8,250 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -24.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -8.34 |
| PEG Ratio | 0 |
| Price to Book value | 2.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|